PDXK

Across TCGA pan-cancer cohorts, PDXK Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated PDXK data layer compared with 28 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in thymoma (THYM), where higher PDXK Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PDXK expression acts as an unfavorable survival marker.

THYM, BRCA, and SCLC are the cancer types where PDXK Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
THYM	OS	Median	III,IV	0.103	0.944	<.001	42	view →
BRCA	OS	Median	III,IV	0.124	0.833	<.001	24	view →
SCLC	DFS	Median	All	0.164	0.631	.002	12	view →
CESC	OS	Median	II,III,IV	0.457	0.768	.031	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
SARC	DFS	Median	All	0.121	0.591	.042	3	view →
COAD	DFS	Median	II,III,IV	0.223	0.687	.029	3	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

PDXK–THYM (OS)

Open the THYM breakdown →